EDITNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Editas Medicine, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$2.42+0.07 (+2.98%)
Close on Oct 19, 2026
- Market cap
- $288.69M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2013 to 2025
Operating margin
-394.9%−246.3 pts over 5 years
Net margin
-395.0%−267.2 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +25.4% | +27.1% | -14.9% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -377.5% | -35.4% | -198.1% | |
| Return on assets | -51.3% | -21.4% | -60.6% | |
| Current ratio | 5.66 | 7.20 | 3.54 | |
| Debt to equity | – | – | 2.15 | |
| Capex to revenue | 57.7% | 7.9% | 1.5% | |
| Diluted shares | 32M | 59M | 89M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Editas Medicine generated $848.86M from operations and spent $26.25M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$848.86M
Used
$26.25M
Capital expenditure$26.25M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-395.0%
×Asset turnover0.15×
×Equity multiplier3.27×
=Return on equity, FY2025-198.1%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -395.0% | 0.15× | 3.27× | -198.1% |
| FY2024 | -733.7% | 0.08× | 1.74× | -98.1% |
| FY2023 | -196.1% | 0.15× | 1.43× | -43.2% |
| FY2022 | -1118.3% | 0.03× | 1.30× | -48.2% |
| FY2021 | -753.6% | 0.04× | 1.32× | -40.6% |
| FY2020 | -127.8% | 0.17× | 1.65× | -35.4% |
| FY2019 | -651.4% | 0.04× | 1.86× | -53.6% |
| FY2018 | -344.3% | 0.08× | 1.79× | -49.5% |
| FY2017 | -876.5% | 0.05× | 1.76× | -70.2% |
| FY2016 | -1605.5% | 0.03× | 7.35× | -377.5% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$160.06M
- Cash generatingOperating cash flow above zero-$165.24M
- Return on assets improvedROA up on the prior year-47.5% → -46.9%
- Earnings backed by cashOperating cash flow above net income-$165.24M vs -$160.06M
- Less leverageLong-term debt to assets fell15.4% → 28.7%
- Better liquidityCurrent ratio rose3.75 → 3.54
- No dilutionShare count did not rise82M → 89M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.06 → 0.12